Johnson & Johnson defied generic competition to post positive Q3 figures, including increases to both turnover and worldwide pharmaceutical sales.

Turnover rose 6.8% to approximately $16bn, whereas worldwide pharmaceutical sales increase 8.9% to $5.98bn.

The company’s biggest earner continued to be anti-inflammatory Remicade, with sales witnessing a 14.6% increase to $1.41bn.

The detrimental effect of generic competition wasn’t completely unfelt, however, as group net earnings fell 6.3% to $3.2bn and US sales fell 6.1%, with domestic sales of antipsychotic medication Risperdal only totalling $8m.

J&J’s Topamax and Procrit / Eprex medications also suffered at the hands of generics, with sales falling by 7.9% and 5.7% respectively.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.